Oppenheimer analyst Matthew Biegler raised the firm’s price target on Oric Pharmaceuticals (ORIC) to $15 from $12 and keeps an Outperform rating on the shares. The firm notes the company reported updated data from the dose exploration portion of ORIC-944’s Phase 1b trial on Thursday alongside Q3 2025 financials. While incremental, Oppenheimer thought the update reinforced efficacy at least as good as mevrometostat but with better pharmacokinetics translating to better safety and tolerability. The firm expects dose expansion data – at some point in the first half of 2026 – to reinforce that benefit further.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORIC:
- Oric Pharmaceuticals price target lowered to $19 from $20 at Wells Fargo
- ORIC Pharmaceuticals Reports Q3 2025 Financial Results
- Oric Pharmaceuticals announces completion of dose exploration for ORIC-944
- Oric Pharmaceuticals Reports Promising ORIC-944 Trial Results
- Oric Pharmaceuticals reports Q3 EPS (33c), consensus (40c)